Management of metastatic colorectal cancer (mCRC) of the liver presents a complex challenge to oncologists and multidisciplinary treatment teams.
Selective internal radiation therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres administered by interventional radiologists is an approved local therapy for the management of mCRC liver tumors.
- Approximately 100,000 doses have been administered in more than 1300 treatment centres worldwide.
- New data from an array of large, multi-centre, international studies support expanded use of SIR-Spheres Y-90 resin microspheres in appropriate patients.
In First Line Treatment of mCRC:
- A post hoc analysis from two RCTs, SIRFLOX and FOXFIRE Global, indicates that the addition of SIR-Spheres Y-90 resin microspheres to chemotherapy in patients with the primary tumour originating from the right-side of the colon, significantly increases the overall survival (OS). These data were presented at European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC), 2017.
- A retrospective analysis (REsect) of data from the first-line SIRFLOX study demonstrated a significant increase in potential resection of liver metastases when SIR-Spheres Y-90 resin microspheres were added to chemotherapy. The data from the REsect study were presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.
- Clinical studies in refractory mCRC have shown that SIR-Spheres Y-90 resin microspheres increase the time to progression and prolong overall survival.1-3 In first-line treatment in mCRC, adding SIR-Spheres Y-90 resin microspheres to FOLFOX-based chemotherapy did not diminish patients' quality of life.4,5
Beyond First Line Treatment in mCRC:
- Radioembolisation with SIR-Spheres Y-90 resin microspheres has demonstrated a clinically significant benefit in overall survival in multiple clinical studies, leading to the recommendation of SIRT with SIR-Spheres Y-90 resin microspheres by the ESMO and the NCCN clinical practice guidelines for colon cancer.
1. Hendlisz et al. J Clin Oncol 2010; 28: 3687–94.
2. Seidensticker et al. Cardiovasc Interv Radiol 2012; 35; 1066‒73.
3. Bester et al. J Vasc Interv Radiol 2012; 23: 96–105.
4. Van Hazel G et al. J Clin Oncol 2016; 34: 1723–1731.
5. Wasan HS et al. Lancet Oncology 2017 Aug 3; ePub doi: 10.1016/S1470-2045(17)30457-6